Martha J Wunsch, MD, FAAP, DFSAM, is the Medical Director of Addiction Medicine with Kaiser Permanente of Northern California and Director of the Addiction Medicine Consultation-Liaison Service at San Leandro Kaiser Hospital. Dr. Wunsch received her education at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Wunsch works in the CDRP, providing any medical treatment for physically healthy individuals needing addiction treatment. Dr. Wunsch also works with other Kaiser Permanente physicians and NP’s as a teacher to improve understanding and management of patients with substance use problems. Dr. Wunsch is a member of the Sub-Board of Addiction for the American Board of Preventive Medicine . She is also the founding co-editor of the Journal of Addiction Medicine. Other member affiliations include the American Academy of Pediatrics, American Society of Addiction Medicine, and the College on Problems on Drug Dependency.
Dr. Hays graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry. In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified in Addiction Medicine, Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School Of Business in May 2001. Dr. Hays serves as coinvestigator on numerous ROI grants involving cocaine, methamphetamine, opioids, cannabis, and alcohol. Dr. Hays served as Chairman of Psychiatry from 1998-2017. He is the Director of Area V of the American Academy of Addiction and is the current President of the American Board of Addiction Medicine (ABAM) and the American College of Academic Addiction Medicine (ACAAM).
Gail D’Onofrio, MD, MS is Professor and Chair of the Department of Emergency Medicine at Yale University and Physician-in Chief of Emergency Services at Yale New Haven Hospital. Boarded in emergency and addiction medicine, she is internationally known for her work in substance use disorders, women’s cardiovascular health, and mentoring physician scientists in developing independent research careers. For the past 25 years she has developed and tested interventions for alcohol, opioids and other substance use disorders, serving as PI on several large NIH, SAMSHA, and CDC studies that have changed clinical practice. Dr. D’Onofrio has a long track record of mentoring junior and senior faculty members both at Yale and throughout the U.S. in multiple specialties. She is the MPI of a NIDA-funded K12 establishing the Yale Drug use, Addiction and HIV Research Scholars (Yale-DAHRS) program, a three-year post-doctoral, interdisciplinary, Mentored Career Development Program with focused training in prevention and treatment of drug use, addiction, and HIV in general medical settings. She has received multiple clinical, leadership and mentorship awards including the Excellence in Mentoring award from the Association for Medical Education and Research in Substance Abuse (2008), Advancing Women in Emergency Medicine award (2016) and the Department of Emergency Medicine Advancement of Women Award (2018) from the Society of Academic Emergency Medicine. She is a founding Board member of Addiction Medicine, now recognized as a new specialty, subspecialty by the American Board of Medical Specialties. An advocate for individuals with opioid use disorder, she is one of the architects of Connecticut Governor’s Strategic Plan to Reduce Opioid Deaths, working with multiple agencies regionally and nationally to change policies and introduce interventions to combat the opioid crisis.
Dr. Adger is Professor of Pediatrics at the Johns Hopkins University School of Medicine and Director of Adolescent Medicine at the Johns Hopkins Hospital, which he joined in 1984. Since that time, he has served as Director of the Substance Abuse Assessment/Intervention Team at The Johns Hopkins Hospital Adolescent Program and as Director of The Johns Hopkins Substance Abuse Faculty Development Programs. In February 1997, Dr. Adger was selected to fill the position of Deputy Director of the White House Office of National Drug Control Policy. In July 1998, he returned to Johns Hopkins to resume his duties as a full-time faculty member. From 1999-2005, he served as Co-Director of the Strategic Planning Initiative funded by HRSA and SAMHSA/CSAT to advise the federal government and others on improving and expanding interdisciplinary education and training of health professionals in substance use disorders. He currently serves as principal investigator and project director of the HRSA-funded Leadership & Education in Adolescent Health project at the Johns Hopkins Hospital and as the faculty leader of the Florence Sabin College in the Johns Hopkins School of Medicine. Dr. Adger also is a past president of the Association for Medical Education and Research in Substance Abuse and a past president of the National Association for Children of Alcoholics.
Dr. Baxter is the President and CEO of the Professional Assistance Program of New Jersey that manages impaired healthcare professionals. He is also the Medical Director for the Division of Addiction Services in the State of New Jersey Department of Human Services, Associate Clinical Professor of Medicine at Rutgers Medical School (formally UMD NJ), and serves as Co-Program Director of Howard University Medical Center’s addiction medicine fellowship. Dr. Baxter completed his undergraduate degrees in Biology and American Civilization at the University of Pennsylvania and earned his Medical Doctorate at Temple University School of Medicine. Dr. Baxter completed his Internship and residency training in Internal Medicine at UMDNJ Cooper Hospital University Medical Center. He sub-specialized in Addiction Medicine through training at Portsmouth Psychiatric Hospital. Dr. Baxter is an Associate Clinical Professor of Medicine at the University of Medicine & Dentistry New Jersey in Newark New Jersey. He is Immediate Past President of the American Society of Addiction Medicine and serves on the Board of Directors. He has also been appointed to the Board of Directors of the National Association of Drug Court Professionals. He has served on a number of National Advisory Councils and Committees which include, SAMSHA, CSAT, NIDA, NIAAA and the FDA. He is a member of many other medical organizations and has many publications.
Dr. Brown is an Associate Professor at The University of Wisconsin Department of Family Medicine and Community Health. Dr. Brown’s primary interests revolve around the treatment and prevention of substance use disorders and their complications in settings outside of the specialist treatment environment (such as primary care, hospitals, pharmacies, and criminal justice settings). He is Board Certified in Family Medicine and in Addiction Medicine. Dr. Brown came to Madison in 2001 to participate in the NIH/NRSA Primary Care Research Fellowship, with focus on addiction health services research, and he attained a PhD in UW’s Dept of Population Health Sciences in 2009. His current research includes investigations in opioid misuse prevention, mobile technology to support recovery, promotion of medication prescribing for alcohol use disorders in primary care, and potential therapeutic applications of psilocybin and MDMA. He serves as a consulting physician in addiction medicine at 2 Madison hospitals, the UW HIV Clinic, and at Access Community Health Centers. Dr. Brown is also the Founding Director of the UW Addiction Medicine Fellowship Program, the Director of the UW fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin.
Dr. O’Connor is the Dan Adams and Amanda Adams Professor and Chief of General Internal Medicine at Yale University School of Medicine and Yale-New Haven Hospital in New Haven, Connecticut. Dr. O’Connor’s research and scholarly work have focused on the interface between primary care and substance abuse. He has written well over 200 papers on these topics that have been published in leading medical journals including The New England Journal of Medicine and JAMA. Dr. O’Connor’s work in the area of opiate detoxification led to research examining the efficacy of opioid maintenance therapy for treating opioid use disorder in primary care and other general medical settings. He and his colleagues at Yale completed a series of studies that look at the effectiveness of methadone and of buprenorphine as the pharmacological agent for this treatment in primary care and emergency medicine settings. Among his accomplishments as Chief of General Internal Medicine at Yale is the recruitment of several academic “generalist” faculty to join efforts to perform research on a broad range of topics related to addiction medicine. The overall goal of this research is to improve access to treatment for patients with substance use disorders to high quality care for their substance use disorders in the context of their general medical care. Dr. O’Connor is also Past President of both The American Board of Addiction Medicine (ABAM) and AMERSA.
Dr. Samet is a graduate of Brandeis University and Baylor College of Medicine. He trained in Internal Medicine including chief residency at Boston City Hospital, Boston University School of Medicine (BUSM), and in a research fellowship at the Massachusetts General Hospital. He has been a primary care physician in Boston since 1983. Dr. Samet is the John Noble Professor of General Internal Medicine at BUSM and Professor of Community Health Sciences at the Boston University School of Public Health. He has been Chief of General Internal Medicine at BUSM/Boston Medical Center since 2002. Dr. Samet has a longstanding commitment to educating physicians about substance use disorders leading NIDA R-25 programs funding the Research in Addiction Medicine Scholars (RAMS) Program and the Chief Resident Immersion Training (CRIT) Program in addiction medicine. He was President of AMERSA (1999- 2001), a member of the Institute of Medicine Committee on “Addressing the Quality Chasm in Mental Health and Addictive Disorders” (2004-2006) and President of the American Board of Addiction Medicine (2012-13). His research interests addressing HIV and substance use and the integration of addiction treatment into mainstream medical care have been supported by NIDA and NIAAA for over 2 decades.
Dr. Sokol is Emeritus Distinguished Professor in the Departments of Obstetrics and Gynecology and Physiology and Emeritus Dean of the Wayne State University School of Medicine and Adjunct Professor, in the Department of Epidemiology and Biostatistics of the Michigan State University College of Human Medicine. At Wayne State he served as Chair of the Departments of ObGyn and of Translational Medicine and as Director of the C.S. Mott Center for Human Growth and Development, as well as Senior Vice President for Medical Affairs for the Detroit Medical Center. Among other honors, he was elected President of the Society for Maternal-Fetal Medicine, the Central Association of Obstetricians and Gynecologists, the Detroit Medical Academy and the Wayne State University Academy of Scholars. He chaired the Liaison Committee for Obstetrics and Gynecology and is Editor-in-Chief of ACOG Update, a monthly CME publication. Dr. Sokol has published extensively on the prevention of perinatal brain damage, particularly as it relates to prenatal exposure to alcohol and cocaine. His honors include many national research awards, a lifetime achievement award from the Society of Maternal-Fetal Medicine and awards from the Wayne State University School of Medicine student body, alumni and school. Dr. Sokol has authored almost 1600 publications, including nearly 400 referenced papers. He has served on four boards of directors of professional theaters, one of which he has chaired, three medical school/university boards, one of which he chaired and serves on many other boards and committees.